DNA
Ginkgo BioworksDNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
If autonomous labs keep converting partner science into repeatable revenue and 2026 cash burn stays within management's reiterated range, Ginkgo can justify some recovery value on the platform story after the Biosecurity divestiture.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +15.0.
What can break
Continuing operations still lost $76.1 million in the quarter, while adjusted EBITDA remained negative at $42 million.
Momentum
70
Value
41
Sentiment
30
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.00 · Bull $12.00 · Bear $4.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-20 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $12.00
Why
Momentum70 · Δ7d +15.0
Value41 · Δ7d +0.1
Sentiment30 · Δ7d -4.4
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
70
34% active weight
Current posture
7d trendImproving
Δ7d
+15.0
Δ21d
-14.1
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
30
33% active weight
Current posture
7d trendSoftening
Δ7d
-4.4
Δ21d
-24.5
Why this grade
Composite grade D. Momentum 70.3 / Value 41.1 / Sentiment 29.9
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$597.07M
Beta
1.56
Shares Out
60.59M
P/E (TTM) · Derived
-1.7
P/S (TTM)
2.83
P/FCF (TTM) · Derived
-2.88
Rev YoY
-56.4%
EPS YoY
-34.4%
Gross Margin
+72.7%
Op Margin
-199.7%
Net Debt
-$561.21M
Current Ratio
4.39
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology